Acelyrin (SLRN) Competitors

Acelyrin (NASDAQ:SLRN) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.

Does the MarketBeat Community prefer SLRN or ETNB?

89bio received 98 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 63.69% of users gave 89bio an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.

Company	Underperform	Outperform
Acelyrin	Outperform Votes 16 55.17%	Underperform Votes 13 44.83%
89bio	Outperform Votes 114 63.69%	Underperform Votes 65 36.31%

Which has more risk and volatility, SLRN or ETNB?

Acelyrin has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Which has better earnings & valuation, SLRN or ETNB?

89bio is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acelyrin	N/A	N/A	-$381.64M	-$2.46	-1.12
89bio	N/A	N/A	-$142.19M	-$3.43	-2.47

Is SLRN or ETNB more profitable?

Acelyrin's return on equity of -44.12% beat 89bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acelyrin	N/A	-44.12%	-39.02%
89bio	N/A	-59.58%	-52.21%

Do analysts rate SLRN or ETNB?

Acelyrin currently has a consensus price target of $9.60, indicating a potential upside of 249.09%. 89bio has a consensus price target of $27.56, indicating a potential upside of 225.33%. Given Acelyrin's higher possible upside, equities research analysts clearly believe Acelyrin is more favorable than 89bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acelyrin	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
89bio	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Does the media prefer SLRN or ETNB?

In the previous week, 89bio had 12 more articles in the media than Acelyrin. MarketBeat recorded 16 mentions for 89bio and 4 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.89 beat 89bio's score of 0.39 indicating that Acelyrin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acelyrin	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
89bio	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in SLRN or ETNB?

87.3% of Acelyrin shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 2.8% of 89bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Acelyrin beats 89bio on 9 of the 16 factors compared between the two stocks.